LENZ Therapeutics Inc

LENZ Therapeutics is a pharmaceutical company focused on the commercialization of VIZZ (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia — the age-related loss of near vision affecting an estimated 128 million people in the United States and 1.8 billion globally. VIZZ is a once-daily, preservative-free eye drop provided in single-dose vials that works as a predominantly pupil-selective miotic, creating a pinhole effect to extend depth of focus and restore clear near vision for up to 10 hours. The company commercializes VIZZ in the United States through eye care professionals, an ePharmacy channel, and a recently launched telehealth platform. Internationally, LENZ is building a network of licensing and distribution partnerships spanning Europe, Canada, Greater China, Australia, New Zealand, and the Middle East, with multiple regulatory filings underway across these markets. Updated Aug 11, 2026